Publié le 6 juin 2018 Mis à jour le 25 mai 2020

The CIRMEN (Centre d’Innovation et de Recherche en Médicine Nucléaire) created by CCC in 2016, in close

interaction with our UMR Inserm/UdA should be highlightened as being devoted to GMP production, formulation and quality control of radiopharmaceuticals for first into human. Such a structure dedicated to fisrt into human clinical transfer is rare in France and open many researches perspectives in radiopharmaceuticals for imaging and targeted therapy. As example, from 2018 CIRMEN is one of the French centers involved in the clinical transfer of 177Lu-PSMA for theranostic management of patients with prostate cancer.